2026 Catalysts: The rise of RNAi

In an analysis of the most highly anticipated clinical and regulatory milestones of 2026, RNA-targeting therapies are everywhere. Antisense and siRNA programs are transitioning from new to established modalities, with 2026 bringing a slate of catalysts ranging from proof-of-concept readouts in new disease spaces to regulatory decisions in large-market indications.

As RNAi and other RNA-targeting drugs advance, they’re also helping define the clinical, regulatory and commercial playbook for other new modalities...